全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:... Kaylyn L. Devlin , Laura M. Lashinger , Stephen D. Hursting
来源:[J].Journal of Mammary Gland Biology and Neoplasia(IF 7.524), 2013, Vol.18 (3-4), pp.267-275Springer
摘要:Abstract(#br)Obesity is associated with increased risk of breast cancer in postmenopausal women and is linked with poor prognosis in pre- and postmenopausal breast cancer patients. The mechanisms underlying the obesity-breast cancer connection are becoming increasingly clear and ...
作者:Laura M. Lashinger , B. Leticia Rodriguez ...
来源:[J].Neoplasia, 2016, Vol.18 (1), pp.33-48Elsevier
摘要:Abstract(#br)In this study, a new compound, 4-( N )-docosahexaenoyl 2′, 2′-difluorodeoxycytidine (DHA-dFdC), was synthesized and characterized. Its antitumor activity was evaluated in cell culture and in mouse models of pancreatic cancer. DHA-dFdC is a poorly soluble, pale y...
作者:Laura M. Lashinger , Ciara H. O’Flanagan ...
来源:[J].Cancer & Metabolism, 2016, Vol.4 (1)Springer
摘要:Abstract(#br) Background(#br)Calorie restriction (CR) prevents obesity and exerts anticancer effects in many preclinical models. CR is also increasingly being used in cancer patients as a sensitizing strategy prior to chemotherapy regimens. While the beneficial effects of CR...
作者:Laura M. Lashinger , B. Leticia Rodriguez ...
来源:[J].Neoplasia: An International Journal for Oncology Research, 2016, Vol.18 (1), pp.33-48DOAJ
摘要:In this study, a new compound, 4-(N)-docosahexaenoyl 2′, 2′-difluorodeoxycytidine (DHA-dFdC), was synthesized and characterized. Its antitumor activity was evaluated in cell culture and in mouse models of pancreatic cancer. DHA-dFdC is a poorly soluble, pale yellow waxy soli...
作者:Laura M. Lashinger , Darren W. Davis ...
来源:[J].Cancer Biology & Therapy(IF 3.287), 2004, Vol.3 (12), pp.1217-1224Taylor & Francis
摘要:Previous studies suggest that antagonists of cyclooxygenases 1 and 2 (COX-1, -2) inhibit angiogenesis in tumor xenografts, but the molecular mechanisms involved remain unclear. Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cycl...
作者:Laura M. Lashinger , Srinivas Chunduru ...
来源:[J].Cancer Biology & Therapy(IF 3.287), 2010, Vol.10 (9), pp.885-892Taylor & Francis
摘要:Purpose: Inhibitors of apoptosis proteins (IAPs) have been shown to contribute to resistance of neoplastic cells to chemotherapy and to biologic antineoplastic agents. Consequently, new agents are being developed targeting this family of proteins. In a panel of bladder cancer cel...
作者:Laura M. Lashinger , Elizabeth Mambo
来源:[J].PLOS ONE(IF 3.73), 2016, Vol.11 (7)PLOS
摘要:MicroRNAs have emerged as ubiquitous post-transcriptional regulators that coordinate many fundamental processes within cells, including those commonly linked to cancer when dysregulated. Profiling microRNAs across stages of cancer progression provides focus as to which microRNAs ...
作者:Laura M. Lashinger , Drew Hays ...
来源:[J].PLOS ONE(IF 3.73), 2014, Vol.9 (5)PLOS
摘要:Calorie restriction (CR) prevents obesity and has potent anticancer effects that may be mediated through its ability to reduce serum growth and inflammatory factors, particularly insulin-like growth factor (IGF)-1 and protumorigenic cytokines. IGF-1 is a nutrient-responsive ...
作者:Laura M. Lashinger , Lisa H. Colbert ...
来源:[J].Current Cancer Drug Targets(IF 4), 2007, Vol.7 (5), pp.484-491Bentham
摘要:The prevalence of obesity, an established epidemiologic risk factor for many cancers, has risen steadily for the past several decades in the U.S. Particularly alarming are the increasing rates of obesity among children, portending continuing increases in the rates of obesity and ...
作者:Laura M. Lashinger , Alison E. Harvey
来源:[J].Carcinogenesis(IF 5.635), 2009, Vol.31 (1), pp.83-89Oxford U Press
摘要:Calorie restriction (CR) is arguably the most potent, broadly acting dietary regimen for suppressing the carcinogenesis process, and many of the key studies in this field have been published in Carcinogenesis . Translation of the knowledge gained from CR research in animal models...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×